Laboratory Monitoring for Quetiapine

Baseline Laboratory Assessment

The FDA recommends obtaining baseline and 6-month follow-up eye examinations when prescribing quetiapine, along with comprehensive metabolic monitoring including fasting glucose, lipid panel, weight/BMI, blood pressure, liver function tests, complete blood count, and ECG 1, 2, 3
Body mass index (BMI), waist circumference, and blood pressure should be established as a metabolic baseline 4
Fasting glucose and HbA1c should be screened to detect diabetes or prediabetes 4
A fasting lipid panel should be assessed to evaluate cardiovascular risk 4
Liver function tests, such as ALT and AST, should be performed as atypical antipsychotics may cause transient transaminase elevations 1, 2, 3
A complete blood count should be established to screen for hematological abnormalities, such as leukocytopenia and thrombocytopenia 1, 2, 3
A pregnancy test should be performed in females of childbearing age 4
An electrocardiogram (ECG) should be assessed to evaluate the QTc interval, as quetiapine can cause QT prolongation 1, 2, 3
An ophthalmologic examination should be performed, as quetiapine was associated with cataract development in animal studies 1, 2, 3

Weight/BMI should be monitored monthly for the first 3 months, then quarterly thereafter 4
Blood pressure should be rechecked at 3 months, then annually 4
Fasting glucose and lipid panel should be reassessed at 3 months, then annually 4

Ophthalmologic examinations should be repeated every 6 months while on quetiapine therapy 1, 2, 3
Liver function tests should be monitored periodically, particularly during the first 3 weeks when transaminase elevations most commonly occur 1, 2, 3
Complete blood count should be monitored periodically to detect potential hematological changes 1, 2, 3

Extrapyramidal symptoms (EPS) should be assessed regularly, though quetiapine has a placebo-level incidence of EPS across its dose range 1, 2, 3
Orthostatic vital signs should be monitored for orthostatic hypotension, particularly during dose titration 1, 2, 3

Patients with pre-existing diabetes or prediabetes require more frequent glucose monitoring, with consideration of monthly checks initially 4
Elderly patients and adolescents warrant closer monitoring for metabolic effects, as adolescents may experience greater weight gain and lipid changes than adults 5